Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from

Related Experiment Video

Updated: Dec 31, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K

Alberto Esteban-Fernández1, Pablo Díez-Villanueva2, Lourdes Vicent3

  • 1Servicio de Cardiología, Hospital Universitario de Móstoles, Madrid, Spain; Universidad Rey Juan Carlos, Madrid, Spain.

Revista Espanola De Geriatria Y Gerontologia
|January 2, 2020
PubMed

Insights

Sacubitril/Valsartan is safe and effective in elderly heart failure patients in real-world practice. Treatment withdrawal in elderly individuals is linked to a poorer prognosis, highlighting the importance of continued therapy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Geriatrics

Background:

  • Elderly patients with heart failure (HF) are underrepresented in Sacubitril/Valsartan trials.
  • The real-world effectiveness and safety of Sacubitril/Valsartan in advanced age are not well-established.

Purpose of the Study:

  • To evaluate the use and safety of Sacubitril/Valsartan in a real-world cohort of elderly patients.
  • To compare adverse events and reasons for withdrawal based on age groups.

Main Methods:

  • Prospective registry of patients initiating Sacubitril/Valsartan in clinical practice.
  • Comparison of baseline characteristics, adverse events, and withdrawal causes across different age groups.

Main Results:

  • Sacubitril/Valsartan was well-tolerated across all age groups, with no significant age-related differences in adverse events.
  • Symptomatic hypotension showed a trend towards higher frequency in older patients.
  • Treatment withdrawal was less frequent in older patients and associated with a poorer prognosis.

Conclusions:

  • Sacubitril/Valsartan is a safe and useful treatment for elderly patients with heart failure with reduced ejection fraction (HF-rEF) in real-world settings.
  • Treatment withdrawal in elderly patients is linked to a poor prognosis.
  • Lower doses of Sacubitril/Valsartan were achieved in elderly individuals.
Abstract

Keywords:
AncianosElderlySacubitril/ValsartanSacubitril/valsartánSafetySeguridad

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
175
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
846
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
154
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
198
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
185
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
751